12:00 AM
 | 
Apr 06, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ICT-107: Phase I discontinued

ImmunoCellular discontinued development of ICT-107, which was in Phase I testing, to conserve resources and to focus on its...

Read the full 74 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >